- Home
- EDRY vs IGC Comparison
EDRY vs IGC Comparison
Compare EDRY & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDRY
- IGC
- Stock Information
- Founded
- EDRY 2018
- IGC 2005
- Country
- EDRY Greece
- IGC United States
- Employees
- EDRY N/A
- IGC N/A
- Industry
- EDRY Marine Transportation
- IGC Biotechnology: Pharmaceutical Preparations
- Sector
- EDRY Consumer Discretionary
- IGC Health Care
- Exchange
- EDRY Nasdaq
- IGC Nasdaq
- Market Cap
- EDRY 31.7M
- IGC 29.4M
- IPO Year
- EDRY N/A
- IGC N/A
- Fundamental
- Price
- EDRY $10.50
- IGC $0.30
- Analyst Decision
- EDRY
- IGC Strong Buy
- Analyst Count
- EDRY 0
- IGC 2
- Target Price
- EDRY N/A
- IGC $3.75
- AVG Volume (30 Days)
- EDRY 9.5K
- IGC 386.9K
- Earning Date
- EDRY 02-24-2025
- IGC 03-04-2025
- Dividend Yield
- EDRY N/A
- IGC N/A
- EPS Growth
- EDRY N/A
- IGC N/A
- EPS
- EDRY N/A
- IGC N/A
- Revenue
- EDRY $65,085,280.00
- IGC $1,236,000.00
- Revenue This Year
- EDRY $31.96
- IGC N/A
- Revenue Next Year
- EDRY $5.32
- IGC $13.38
- P/E Ratio
- EDRY N/A
- IGC N/A
- Revenue Growth
- EDRY 39.04
- IGC 1.64
- 52 Week Low
- EDRY $10.04
- IGC $0.27
- 52 Week High
- EDRY $24.84
- IGC $0.91
- Technical
- Relative Strength Index (RSI)
- EDRY 39.27
- IGC 38.51
- Support Level
- EDRY $10.40
- IGC $0.29
- Resistance Level
- EDRY $10.83
- IGC $0.33
- Average True Range (ATR)
- EDRY 0.51
- IGC 0.01
- MACD
- EDRY 0.01
- IGC -0.00
- Stochastic Oscillator
- EDRY 7.58
- IGC 15.00
About EDRY EuroDry Ltd.
EuroDry Ltd is a holding company. It is a provider of ocean-going transportation. The company owns and operates dry bulk carriers that transport bulks such as iron ore, coal, and grains, and minor bulks such as bauxite, phosphate, and fertilizers.
About IGC IGC Pharma Inc.
IGC Pharma Inc develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol-based formulation that is in a 146-person Phase 2 clinical trial for agitation in dementia due to Alzheimer's. IGC also markets a wellness brand, Holief, that targets women experiencing premenstrual syndrome and menstrual cramps.